SCHEMBL2228538

SCHEMBL2228538

O=C(OCc1cscn1)N1CCC(CCOc2cccc(Oc3ccccc3)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 1/20 0.45
TEAD3 Q99594 1/20 0.45
MGLL Q99685 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CSF1R P07333 1/20 0.41
KDR P35968 1/20 0.41
LMNA P02545 1/20 0.41
GRIN2B Q13224 4/20 0.40
GAA P10253 1/20 0.40
FAAH O00519 1/20 0.40
CHRM4 P08173 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTR1A P08908 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
HTR2C P28335 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228891 0.94 TEAD1 (0.50) TEAD1TEAD3MMP2MMP9CSF1R
SCHEMBL2229435 0.91 TEAD1 (0.45) TEAD1TEAD3MMP2MMP9GRIN2B
SCHEMBL2227489 0.89 MMP2 (0.42) TEAD1TEAD3MMP2MMP9GRIN2B
SCHEMBL2229045 0.87 MMP2 (0.45) TEAD1TEAD3MMP2MMP9GRIN2B
SCHEMBL2229801 0.86 KMT2A (0.47) TEAD1TEAD3MGLLMMP2MMP9
SCHEMBL2231117 0.86 TEAD1 (0.47) TEAD1TEAD3MMP2MMP9GRIN2B
SCHEMBL2227170 0.86 MGLL (0.50) TEAD1TEAD3MGLLMMP2MMP9
SCHEMBL2365563 0.86 MMP2 (0.40) TEAD1TEAD3MMP2MMP9GRIN2B
SCHEMBL2230299 0.85 MEN1 (0.41) TEAD1TEAD3MGLLMMP2MMP9
SCHEMBL2229931 0.84 TEAD1 (0.46) TEAD1TEAD3MMP2MMP9GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US claimed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP claimed
CN-102803258-A Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use SANOFI AVENTIS 2012-11-28 CN claimed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US claimed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO claimed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 TEAD1 4192/4885TEAD3 3201/4885MGLL 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.